Her-2 neu expression in cervical intraepithelial neoplasia and carcinoma of cervix

Abstract

Currently radiotherapy, cisplatin based chemo-radiation and surgery are used in combination for treating cervical cancer according to stage of the tumor. Patients with advanced disease stage have limited treatment options with median overall survival of less than one year. Therefore, there is increasing interest in using targeted therapy as a treatment modality. There are controversial views of various authors regarding role of Her-2 neu targeted therapy in cervical carcinoma. The present study was conducted to evaluate the expression of Her-2 neu in Pre-malignant and Malignant lesions of cervix and attempt its correlation with histological type, grade and stage of the tumor. A cross-sectional observational study was conducted from January 2017 to January 2018 including a total of 55 patients with either pre-malignant and malignant lesions of cervix. Rabbit monoclonal Antibody to Her2/ErBb2 from BioGenex was used for staining. Intensity of Her-2 neu expression was graded according to the 2014 ASCO/CAP guidelines for Her-2 reporting. There was higher expression of Her-2 neu expression in HSIL then LSIL. There was significant correlation between Her-2 neu expression and histological types of malignant lesions. There was no significant correlation between Her-2 neu expression and pre-malignant lesions, stage of cervical carcinoma and grades of squamous cell carcinoma. Her-2 neu has a role in higher grade of cervical lesions but studies with larger cohorts are needed to comment upon its definite role in targeted therapy.